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Purpose: The aim of this study was to compare the effects of olmesartan combined with either 
azelnidipine or amlodipine on central blood pressure (CBP) and left ventricular mass index 
(LVMI) in hypertensive patients.
Patient and methods: Patients with brachial systolic BP $ 140 mmHg and/or diastolic 
BP $ 90 mmHg received olmesartan monotherapy (20 mg daily) for 12 weeks. The patients 
were then randomly assigned to fixed-dose add-on therapy with azelnidipine (16 mg daily) 
or amlodipine (5 mg daily) (25 patients/group) for a further 24 weeks. CBP and LVMI were 
measured at baseline and at the end of the study.
Results: Baseline characteristics were similar in both groups. The decrease in brachial BP was 
similar in both groups. CBP and LVMI decreased significantly in both groups (both, P , 0.001). 
However, the decreases in CBP and LVMI were significantly greater with   olmesartan/
azelnidipine than with olmesartan/amlodipine (CBP, P , 0.001; LVMI, P = 0.002).
Conclusions: These findings indicate that olmesartan/azelnidipine had greater effects on CBP 
and LVMI than did olmesartan/amlodipine, even though the reduction in brachial BP was similar 
in both groups. These differential effects on CBP and LVMI may have important implications 
for cardiovascular risk reduction.
Keywords: central blood pressure, left ventricular mass index, augmentation index, 
brachial-  ankle pulse wave velocity, olmesartan/azelnidipine
Introduction
When blood pressure (BP) control is inadequate with a single antihypertensive drug, 
the use of two or three drugs in combination is often necessary to achieve the target 
blood pressure. Combination therapy with an angiotensin II receptor blocker (ARB) 
and a diuretic or an ARB plus a calcium channel blocker (CCB) are recommended in 
the current Japanese Society for Hypertension guidelines.1 Several studies, including 
the ASCOT-CAFÉ2 and the Strong Heart Study,3 have emphasized the importance of 
targeting central blood pressure (CBP) rather than brachial BP in terms of cardiovas-
cular disease outcomes. For example, the ASCOT-CAFÉ study compared the efficacy 
of amlodipine with that of atenolol, a β-blocker, and showed that both regimens had 
very different effects on central aortic pressures and hemodynamics despite similar 
effects on brachial BP.2 Meanwhile, in the Strong Heart Study,3 central pulse pres-
sure was more strongly related to vascular hypertrophy, extent of atherosclerosis, and 
cardiovascular events than was brachial BP.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Several studies have also shown that an ARB in 
combination with a CCB significantly improves CBP.4,5 
Notably, however, the influence of CCBs on BP cannot be 
explained as a class effect because of differences in the effects 
of azelnidipine and amlodipine.6–8
Unfortunately, unlike amlodipine, few studies have 
examined the effects of azelnidipine on CBP. Moreover, 
to our knowledge, no studies of combination therapy have 
been conducted in Japan. In this context, we conducted 
the current study (Azelnidipine plus OlmesaRTAn versus 
amlodipine plus olmesartan; AORTA study) to determine 
the effects of adding either azelnidipine or amlodipine to 
ongoing olmesartan in patients with inadequate BP control 
on a standard dose of olmesartan.
Methods
Patients
Patients aged 36–75 years were recruited from among 
outpatients of the Department of Internal Medicine at Clinic 
Jingumae (Kashihara, Japan) between March 2007 and 
October 2008. We initially enrolled consecutive hypertensive 
patients with or without current treatment who agreed 
to participate in this study. Hypertension was defined as 
clinic-measured systolic BP (SBP) $ 140 mmHg and/or 
diastolic BP (DBP) $ 90 mmHg on two different occasions 
or by a previous diagnosis of hypertension with current 
antihypertensive therapy. Patients were excluded if they 
had secondary hypertension, arrhythmia, current treatment 
for congestive heart failure, a history of stroke or coronary 
artery disease, clinically significant valvular heart disease, 
renal insufficiency (serum creatinine $2 mg/dL), mental 
disorders, severe noncardiovascular disease (eg, cancer or 
liver cirrhosis), or chronic inflammatory disease. Patients 
who were already being treated with olmesartan were also 
excluded. Written informed consent was obtained from all 
of the patients participating in the study. The study protocol 
was approved by the Institutional Ethical Committee.
Study design
The AORTA study was a 24-week, prospective, randomized, 
open-label parallel-group study comprising a 12-week run-in 
period followed by a 24-week randomized treatment period. 
The design of the study is summarized in Figure 1. Patients 
who were already being treated with antihypertensive drugs 
switched their current antihypertensive medications to olm-
esartan monotherapy. If the clinic SBP exceeded 200 mmHg 
and/or DBP exceeded 115 mmHg at any time during the 
run-in period, the patient was withdrawn from the study. 
Both regimens were given at fixed doses for 24 weeks; dose 
titration was not permitted. The patients were instructed to 
take their medications after breakfast and were not permit-
ted to use any antihypertensive drugs other than the study 
drugs. Other drugs that had the potential to interfere with 
the safety or efficacy of the study drugs were also not 
permitted. Brachial BP, heart rate (HR), CBP, normalized 
augmentation index (AIx@75), brachial-ankle pulse wave 
velocity (baPWV), and left ventricular mass index (LVMI) 
were measured at baseline and at the end of the 24-week 
treatment phase.
Measurement of cBP, Aix@75,  
and baPWV
The pulse pressure waveform of the radial artery was 
recorded using an automated tonometry system (HEM-
9000AI; Omron Healthcare, Kyoto, Japan) with the patient 
in the sitting position after resting for $5 minutes. The 
waveform was automatically calibrated using the built-in 
oscillometric brachial sphygmomanometer, and the peak and 
trough of the radial pressure wave were adjusted to brachial 
SBP and DBP, respectively. An algorithm programmed into 
the HEM-9000AI system performed automatic online detec-
tion of the second peak (late systolic inflection) based on the 
second maxima of the fourth derivative of the radial pressure 
waveform to determine the radial AI as well as the late or 
second SBP (SBP2). This algorithm is described in more 
detail elsewhere.9 The height of the second peak corresponds 
to the SBP2 value obtained by the HEM-9000AI. SBP2 is 
very close to invasively recorded aortic CBP10 and was used 
Untreated or
treated patients
with
hypertension
Azelnidipine (16 mg daily)
Amlodipine (5 mg daily)
Olmesartan (20 mg daily)
Week −12 02 4
Visit CBP
Alx@75
PWV
LVMI
CBP
Alx@75
PWV
LVMI
a
Run-in period Treatment period
Figure 1 Study protocol.
Note: aPatients were randomized at the end of the run-in period if clinic-measured 
SBP was $140 mmHg and/or DBP was $90 mmHg.
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; cBP, 
central blood pressure; Aix@75, normalized augmentation index; PWV, pulse wave 
velocity; LVMi, left ventricular mass index.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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as an estimate of CBP. CBP determined by the HEM9000-AI 
was reported to be comparable with CBP estimated using a 
generalized aorta–radial transfer function.11,12 The AI was 
calculated using the formula (SBP2 − DBP)/(the first peak 
SBP − DBP) × 100. Because AI is influenced by the HR, it 
was normalized for an HR of 75 bpm (AIx@75) as proposed 
by Wilkinson et al.13 baPWV was also used to assess arterial 
stiffness. baPWV was performed as described previously.14 
Briefly, baPWV was determined from the pulse waveforms 
recorded from both forearms and both ankles using the for-
mula PWV (Omron Healthcare). This parameter was mea-
sured in patients who had been lying in the supine position 
for at least 5 minutes. baPWV measurements were repeated 
twice to confirm reproducibility, and the deviation between 
measurements was within 5%. The mean value on the right 
side was used as the baPWV value in each patient.
Measurement of LVMi
M-mode echocardiography was performed under 2-  dimensional 
guidance using a Vivid S6 ultrasound system (GE Healthcare, 
Milwaukee, WI) with a 3-MHz transducer. LVMI was mea-
sured by standard M-mode echocardiography and determined 
using the formula reported by Devereux et al.15
Statistical analysis
Data are shown as means ± SD. Differences between the two 
groups at baseline were analyzed using unpaired t tests for 
continuous variables and χ2 tests for categorical variables. 
Paired t tests were used for within-group comparisons while 
unpaired t tests were used for between-group comparisons. 
Values of P , 0.05 (2-sided) were considered statistically 
significant. SAS software (v 8.2; SAS Institute Inc, Cary, 
NC) was used for all analyses.
Results
Baseline characteristics
During the run-in period, 95 patients received 20 mg 
olmesartan monotherapy once daily. At the end of the 
run-in period, 43 patients discontinued because they did 
not meet the BP criteria. Thus, 52 patients with a clinic 
SBP $ 140 mmHg and/or DPB $ 90 mmHg were eligible 
and were randomized to receive add-on azelnidipine (16 mg 
daily) or amlodipine (5 mg daily) to ongoing olmesartan. 
Patients were randomized using the permuted block method. 
Of the 26 patients randomized to the olmesartan/azelnidipine 
regimen, one was excluded after missing the final assess-
ment visit. Of the 26 patients randomized to the   olmesartan/
amlodipine regimen, one was excluded after missing 
Table 1 Baseline characteristics
Olmesartan/
Azelnidipine 
(n = 25)
Olmesartan/ 
Amlodipine 
(n = 25)
P-value
Age (years) 65.8 ± 4.1 67.5 ± 4.6 0.17
Sex (male, %) 17 (68%) 18 (72%) 0.75
BMi (kg/m2) 25.8 ± 1.0 25.8 ± 1.3 0.97
SBP (mmHg) 151.8 ± 5.6 151.6 ± 4.4 0.89
DBP (mmHg) 85.8 ± 5.2 86.2 ± 4.7 0.75
cBP (mmHg) 147.3 ± 5.4 146.3 ± 3.5 0.46
HR (bpm) 73.5 ± 5.8 73.7 ± 7.0 0.93
Aix@75 (%) 91.9 ± 4.5 92.7 ± 3.3 0.48
baPWV(cm/sec) 1895.9 ± 201.0 1848.4 ± 174.0 0.38
LVMi (g/m2) 122.8 ± 3.0 122.8 ± 2.8 0.96
egFR (mL/min/1.73 m2) 66.4 ± 4.1 66.4 ± 4.5 0.97
HbA1c (%) 5.8 ± 1.2 5.7 ± 1.1 0.92
LDL-c (mg/dL) 110.3 ± 16.5 112.0 ± 12.3 0.67
HDL-c (mg/dL) 55.9 ± 9.0 55.4 ± 8.3 0.83
Tg (mg/dL) 152.7 ± 75.4 170.4 ± 61.9 0.37
UA (mg/dL) 5.4 ± 1.0 5.6 ± 0.8 0.53
Note: Values are means ± standard deviation or n (%).
Abbreviations:  BMi,  body  mass  index;  SBP,  systolic  blood  pressure;  DBP, 
diastolic blood pressure; cBP, central blood pressure; HR, heart rate; Aix@75, 
normalized augmentation index; baPWV, brachial-ankle pulse wave velocity; LVMi, 
left ventricular mass index; eGFR, estimated glomerular filtration rate; LDL-C, low-
density  lipoprotein  cholesterol;  HDL,  high-density  lipoprotein  cholesterol;  Tg, 
triglyceride; UA, uric acid.
the final assessment visit. Thus, the population included 
25 patients assigned to each regimen. The characteristics of 
the patients at the start of the randomized phase of the study 
(ie, baseline) are shown in Table 1. The baseline BP and other 
hemodynamic parameters were similar in both groups.
changes in brachial BP, cBP, and HR
Brachial BP and CBP decreased significantly in both 
treatment groups (all, P , 0.001; Table 2). However, the 
decrease in CBP was significantly greater in the olmesartan/
azelnidipine group than in the olmesartan/amlodipine group 
(−14.0 ± 4.3 vs −8.3 ± 3.7 mmHg, respectively, P , 0.001; 
Figure 2A), whereas the decrease in brachial BP was similar 
in both groups. The magnitude of the decrease in HR was 
significantly greater in the olmesartan/azelnidipine group 
than in the olmesartan/amlodipine group (−4.4 ± 4.3 vs 
1.1 ± 3.3 bpm, respectively, P , 0.001; Figure 2B).
changes in Aix@75
The AIx@75 decreased significantly in both treatment 
groups between baseline and endpoint (both P , 0.001; 
Table 2). The magnitude of the decrease in AIx@75 was 
significantly greater in the olmesartan/azelnidipine group 
than in the olmesartan/amlodipine group (−8.4 ± 5.4 vs 
−4.3 ± 3.7%, respectively, P , 0.001; Figure 2C).Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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baPWV decreased significantly in both treatment groups 
between baseline and endpoint (olmesartan/azelnidipine, 
P , 0.001; olmesartan/amlodipine, P = 0.003; Table 2). The 
magnitude of the decrease in baPWV was significantly greater 
0
−2
−4
−6
−8
−10
−12
−14
−16
−18
−20
−22
C
h
a
n
g
e
 
i
n
 
C
B
P
 
(
m
m
H
g
)
Olmesartan/
Azelnidipine
Olmesartan/
Amlodipine
P < 0.001
A
C
h
a
n
g
e
 
i
n
 
H
R
 
(
b
p
m
)
Olmesartan/
Azelnidipine
Olmesartan/
Amlodipine
P < 0.001
6
4
2
0
−2
−4
−6
−8
−10
−12
B
C
h
a
n
g
e
 
i
n
 
A
l
x
@
7
5
 
(
%
)
Olmesartan/
Azelnidipine
Olmesartan/
Amlodipine
P < 0.001
0
−2
−4
−6
−8
−10
−12
−14
−16
C
Figure 2 (Continued)Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
387
The AORTA Study
Discussion
In this study, we found that, during 24 weeks of combination 
therapy, olmesartan/azelnidipine elicited significantly 
greater decreases in CBP than olmesartan/amlodipine, even 
though the decrease in brachial BP was similar with both 
  treatments. In addition, AIx@75, baPWV , and HR all showed 
  significantly greater decreases with olmesartan/azelnidipine 
than with olmesartan/amlodipine.
Different hemodynamic effects of the two regimens may 
explain why the decrease in CBP was greater with olmesartan/
azelnidipine than with olmesartan/amlodipine, a concept sup-
ported by the greater decrease in AIx@75 with olmesartan/
azelnidipine than with olmesartan/amlodipine. AI is a measure 
of the contribution of wave reflection to the aortic waveform 
and depends on the pulse wave velocity, and magnitude and 
site of the reflected pressure wave, and thus provides a compos-
ite measure of large artery (systemic) stiffness.16 Increases in 
CBP and the AIx@75 are influenced by pressure waves that are 
reflected back toward the heart from branch points throughout 
the arterial tree. PWV is also a measure of arterial stiffness. 
When arteries become sclerosed, PWV is elevated, promoting 
an acceleration of the waves reflected back.   Renin–angiotensin 
system (RAS) inhibitors and CCBs act directly on peripheral 
sites, alter the arterial smooth muscle, and thus reduce pres-
sure wave reflection.2,17–21 In fact, RAS inhibitors and CCBs 
have been shown to decrease CBP by reducing pressure wave 
reflection.22 Compared with amlodipine, azelnidipine may 
elicit greater reductions in CBP by inducing greater decreases 
in pressure wave reflection. Thus, the main mechanism 
responsible for CBP lowering associated with olmesartan/
azelnidipine may involve reductions in the magnitude of and 
potential delays in pressure wave reflection.
Figure 2 changes in central blood pressure (cBP) (A), heart rate (HR, beats per 
minute [bpm]) (B), normalized augmentation index (Aix@75) (C), baPWV (D), and 
left ventricular mass index (LVMi) (E) from baseline to week 24.
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Figure 3 changes in central blood pressure (cBP) and left ventricular mass index 
(LVMi) between baseline and endpoint.
in the olmesartan/azelnidipine group than in the olmesartan/
amlodipine group (−275.9 ± 161.2 vs −101.6 ± 155.6 cm/
second, respectively, P , 0.001; Figure 2D).
changes in LVMi
LVMI decreased significantly in both treatment groups 
between baseline and endpoint (both, P , 0.001). Notably, 
the magnitude of the decrease in LVMI was significantly 
greater in the olmesartan/azelnidipine group than in the 
olmesartan/amlodipine group (−6.6 ± 3.4 vs −3.0 ± 2.5 g/m2, 
respectively, P = 0.002; Figure 2E). We also detected a strong 
correlation between the change in CBP and the change in 
LVMI (R2 = 0.6262, P , 0.0001; Figure 3).
Adverse events
All of the patients who entered the randomized phase of the 
study completed the study without experiencing any serious 
adverse events or drug-related adverse events.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
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Another mechanism that may explain the decrease in 
CBP in this study is that olmesartan/azelnidipine decreased 
the HR whereas olmesartan/amlodipine did not. These results 
are consistent with previous reports in which azelnidipine 
decreased clinic-measured HR and 24-hour HR, whereas 
amlodipine increased both of these parameters, despite 
similar BP reductions.8,23 It was also reported that, after 
switching from amlodipine, azelnidipine exhibited hypoten-
sive effects compared with amlodipine, and significantly 
decreased HR and the total number of extrasystole phases.24 
Noradrenaline levels and the LF/HF ratio were significantly 
decreased, and the washout rate was significantly reduced on 
123I-MIBG myocardial scintigraphy. These findings suggest 
that azelnidipine inhibits the enhancement of sympathetic 
nervous activity.24 These differences in the effects of azelni-
dipine and amlodipine can also be explained by the finding 
that azelnidipine exerts stronger inhibition of sympathetic 
activity in the vasodilation-induced baroreceptor reflex than 
does amlodipine.7
Experimental studies have also shown that azelnidipine 
dose-dependently reduces HR.25 In another study, azelnidipine 
suppressed cardiac hypertrophy, fibrosis, NADPH oxidase, 
and superoxide levels in stroke-prone spontaneously 
  hypertensive rats more potently than amlodipine, and was 
associated with lower HR than amlodipine.26 Azelnidipine 
also caused a greater reduction than amlodipine in the beat 
rate of the sinus node/atrial preparation of these rats.26 Based 
on these findings, olmesartan/azelnidipine may reduce CBP 
via the HR-lowering effect of azelnidipine.
In general, AI and CBP increase with HR lowering. In 
this study, however, both parameters decreased despite HR 
lowering. This result is consistent with a previous report 
showing that olmesartan/azelnidipine significantly decreased 
HR, AI, CBP, and Aortic PWV (AoPWV) by more than 
olmesartan/hydrochlorothiazide.5 The HR-lowering effect 
of   azelnidipine through its sympathetic inhibition may be 
at least partly responsible for the greater effect of the olm-
esartan/azelnidipine combination on AoPWV .5 We measured 
baPWV rather than AoPWV , but it has been reported that 
baPWV correlates well with AoPWV .27
In this study, we also found that the decrease in LVMI 
was significantly greater with olmesartan/azelnidipine than 
with olmesartan/amlodipine. The strong correlation between 
change in LVMI and change in CBP (Figure 3), suggests that 
the greater reduction in LVMI in the olmesartan/azelnidipine 
group may be related to the greater reduction of CBP in that 
group. In hypertension the pressure reflection wave during 
systole augments central ascending aortic BP.17,28,29 As a 
result, the LV must provide greater force during ejection to 
overcome the augmented pressure.30,31 AI, CBP and wasted 
LV effort were positively associated with LV hypertrophy in 
untreated hypertensive patients.32 It was also reported that 
an increase in the ascending aortic AI caused by a reflected 
wave may be involved in the formation of LV hypertrophy.33 
Moreover, in the REASON study, the greater change in LV 
mass was linked to CBP but not brachial BP.34 Thus, LVMI 
lowering associated with olmesartan/azelnidipine may have 
been due to reductions in CBP and AI.
It has been reported that lowering BP with the additional 
use of azelnidipine is associated with improvements in LV 
diastolic performance (ie, an increase in the e’ velocity), 
a reduction in LV filling pressure (a decrease in the E/e’ ratio) 
and a decrease in the brain natriuretic peptide level in patients 
with hypertension and a preserved systolic function.35 Among 
patients in whom amlodipine was switched to azelnidipine, 
BP and HR decreased significantly, and these reductions were 
associated with an increase in the e’ velocity.35 Therefore, 
regression of LVMI may be related to the improvements in 
LV diastolic function elicited by azelnidipine.
CBP, AI, and LV hypertrophy are independent predictors 
of cardiovascular morbidity in patients with hypertension.2,36,37 
Epidemiological studies have shown that an increased HR 
is associated with a higher incidence of cardiovascular 
diseases and a worse prognosis.38,39 Tachycardia caused by 
reflex activation of the sympathetic nervous system is a 
major adverse effect of CCB therapy. However, unlike amlo-
dipine, azelnidipine has been shown to inhibit sympathetic 
activity,40 suggesting that tachycardia is unlikely to occur 
with azelnidipine. Indeed, we found that the HR decreased 
with azelnidipine, but not with amlodipine.
Some limitations of this study should be discussed. First, 
this was not a double-blind randomized trial, meaning the 
possibility of a significant bias cannot be excluded. However, 
measurements were performed by a single clinical investiga-
tor who was blinded to the treatment allocation; therefore, 
there was no bias in the measurement and evaluation of 
laboratory data. Second, the study period was relatively 
short and the sample size was small; longer and larger stud-
ies are necessary to evaluate the long-term effects of these 
combination therapies on arterial structure. Third, the dose 
of azelnidipine used might also have influenced the results. 
However, we used the standard clinical dose of azelnidipine 
(ie, 16 mg/day), a dose that achieved similar reductions in 
BP to that achieved by a standard dose of amlodipine (ie, 
5 mg/day). Finally, the CBP results are based solely on radial 
tonometry data. Radial tonometry is comfortable for patients Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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and easy to use in a clinical setting, but it is subject to inter-
observer variability and the results may not be an accurate 
reflection of actual pressures. Therefore, future studies should 
validate these results using direct pressure measurements.
Conclusion
In conclusion, the AORTA study revealed that olmesartan in 
combination with azelnidipine elicited greater reductions in 
CBP and LVMI compared with olmesartan in combination 
with amlodipine, even though the reduction in brachial BP 
was similar with both regimens. CBP is an independent pre-
dictor of cardiovascular morbidity in hypertensive patients. 
Therefore, the superior effects of olmesartan/azelnidipine 
therapy on central hemodynamics may be associated with 
more favorable cardiovascular outcomes than with olmesar-
tan/amlodipine. Such differential effects may be important 
for cardiovascular risk reduction and warrant large-scale, 
long-term clinical trials to confirm this hypothesis.
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